中国药房2012，Vol.23Issue(19)：1794-1799,6.DOI:10.6039/j.issn.1001-0408.2012.19.29
川芎嗪治疗糖尿病肾病的系统评价
Effect of Tetramethylpyrazine on Diabetic Nephropathy: A Systematic Review
田春娟 1程春瑞 2熊奕 3欧书钦2
作者信息
- 1. 重庆市北碚区第二人民医院内科,重庆400712
- 2. 重庆市第四人民医院内分泌科,重庆400014
- 3. 重庆邮电大学医院内科,重庆400065
- 折叠
摘要
Abstract
OBJECTIVE: To evaluate the effectiveness and safety of tetramethylpyrazine in the treatment of diabetic nephropathy (DN). METHODS: All random control trials (RCTs) of tetramethylpyrazine in the treatment of diabetic nephropathy were retrieved from CNKI, Wanfang database, VIP, PubMed, Cochrane Library, OVID and EMBASE. The Cochrane Collaboration's RevMan 5.0 and Stata Meta-analysis software were used for Meta-analysis. RESULTS: 28 RCTs were included, involving 2023 DN patients. The quality of including trials was low, and the funnel plot showed asymmetry. The results of Meta-analysis indicated that tetramethylpyrazine could reduce urinary albumin excretion rate (UAER) , 24 hours urinary protein and serum creatinine (Scr) ; tetramethylpyrazine was inferior to angiotensin converse enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) or alprostadil in respect of decreasing UAER and 24 hours urinary protein. No adverse drug reaction was found. CONCLUSION: Tetramethylpyrazine may be safe and effective in the treatment of diabetic nephropathy, and large-scale and high quality RCTs are required for further study.关键词
川芎嗪/糖尿病肾病/系统评价/随机对照试验/Meta分析Key words
Tetramethylpyrazine/ Diabetic nephropathy/ Systematic review/ Random control clinical trial/ Meta-analysis
分类
医药卫生引用本文复制引用
田春娟,程春瑞,熊奕,欧书钦..川芎嗪治疗糖尿病肾病的系统评价[J].中国药房,2012,23(19):1794-1799,6.
